New injection approved by the USFDA for AurobindoPharma
By Q4 of FY23, Amphotericin B Liposome for Injection is anticipated to go on sale.
admin
0
37
The US Food and Drug Administration (USFDA) has granted final approval for Amphotericin B Liposome for Injection to AurobindoPharma's wholly-owned subsidiary firm, EugiaPharmaSpecialities Limited.
Amphotericin B Liposome for Injection, the approved product, is bioequivalent and therapeutically equivalent to AstellasPharma US, Inc.'s AmBisome Liposome for Injection, the reference listed drug (RLD).
By Q4 of FY23, the product is anticipated to be released. According to IQVIA, the market size for the approved product is anticipated to be roughly $145 million for the 12 months ending September 2022.
For the treatment of fungus infections, it is recommended.
